Adverse Effects of Highly Active Antiretroviral Therapy in Developing Countries
Open Access
- 15 October 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (8), 1093-1101
- https://doi.org/10.1086/521150
Abstract
Recent increases in access to highly active antiretroviral therapy (HAART) have made the management of drug toxicities an increasingly crucial component of human immunodeficiency virus (HIV) care in developing countries. The spectrum of adverse effects related to HAART in developing countries may differ from that in developed countries because of the high prevalence of conditions such as anemia, malnutrition, and tuberculosis and frequent initial presentation with advanced HIV disease. The severity of adverse effects may vary as a result of host genetics and diagnostic delays attributable to inadequate laboratory monitoring. This article reviews current knowledge about toxicities related to HAART in resource-limited regions, which are in the process of rapid treatment scale-up. We conclude that initiating HAART before advanced immunosuppression, titrating doses in single-pill drug combinations to differences in patients' body weights, providing more intensive laboratory monitoring during the initial months of therapy, and providing access to less-toxic nucleoside reverse-transcriptase inhibitors may decrease the incidence of toxicities related to HAART in resource-limited regions.This publication has 90 references indexed in Scilit:
- Evaluation of antiretroviral therapy results in a resource‐poor setting in Blantyre, MalawiTropical Medicine & International Health, 2005
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001AIDS, 2003
- Population pharmacokinetic meta-analysis with efavirenzInt. Journal of Clinical Pharmacology and Therapeutics, 2002
- Population pharmacokinetics of nevirapine in an unselected cohort of HIV‐1‐infected individualsBritish Journal of Clinical Pharmacology, 2002
- Immune Reconstitution Inflammatory SyndromeMedicine, 2002
- Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infectionsJournal of Hepatology, 2002
- Once‐Daily Combination Therapy with Emtricitabine, Didanosine, and Efavirenz in Human Immunodeficiency Virus–Infected PatientsThe Journal of Infectious Diseases, 2000
- Peripheral Neuropathy with Nucleoside AntiretroviralsDrug Safety, 1998
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexThe New England Journal of Medicine, 1987